Acasti reports topline triglyceride results from phase 3 trilogy 2 study of capre

Acasti pharma reports topline triglyceride results from phase 3 trilogy 2 study of capre in patients with severe hypertriglyceridemia.acasti pharma inc - reported a 30.4% median reduction in triglyceride levels among all patients receiving capre.acasti pharma inc - trilogy 2 study did not meet its primary endpoint.acasti pharma inc - will not file a new drug application nda with fda and does not plan to conduct additional clinical trials for capre.acasti pharma inc - capre was well tolerated in trilogy 2, with a safety profile similar to placebo.
ACST Ratings Summary
ACST Quant Ranking